A new article published by a pair of UK scientists predicts a brighter future for mesothelioma patients thanks to a growing understanding of the disease and how to treat it. Malignant mesothelioma is the cancer most closely associated with asbestos. Although only a small percentage of asbestos-exposed people go on to develop mesothelioma, those who do face a grim prognosis. Doctors learned early on that standard cancer treatments rarely work for patients with mesothelioma. But Anna Bibby and Nick Maskell with Bristol Medical School and the North Bristol Lung Centre say the large amount of high-quality mesothelioma research conducted in the last decade has moved medicine closer to finding a cure for this intractable cancer. Important Mesothelioma Research Findings In … Continue reading Study Predicts New Mesothelioma Therapies on the Horizon
There is new evidence that low doses of the drug Opdivo (nivolumab) may extend lung cancer survival as well as the standard dose—at a much lower cost. The news may have implications for people with the lung-related asbestos cancer, malignant mesothelioma, who are also sometimes treated with Opdivo. Pleural mesothelioma is a hard-to-treat cancer that grows on the lining around the lungs and causes many of the same symptoms as lung cancer. Some evidence has suggested that Opdivo, an immunotherapy drug already approved for the treatment of recurrent lung cancer, may soon become the first drug approved for recurrent mesothelioma, too. Now, a newly-published Korean study finds that patients may not need as much of the drug as originally thought … Continue reading Opdivo for Malignant Mesothelioma: Could a Lower Dose Work?
As part of what they call the “new era” of mesothelioma immunotherapy research, doctors in Ohio and Florida have just published the case report of a man whose pleural mesothelioma was stopped in its tracks with the drug nivolumab. The case is detailed in the latest issue of the American Journal of Case Reports by researchers at the University of Florida and The Christ Hospital in Cincinnati. Details of the Mesothelioma Case Report The patient in question had been diagnosed with malignant pleural mesothelioma, a deadly cancer that typically carries a poor prognosis, even with aggressive treatment. In fact, even though chemotherapy with a combination of cisplatin and pemetrexed (Alimta) is considered the standard-of-care for malignant mesothelioma, fewer than 4 … Continue reading Immunotherapy Drug Produces ‘Exceptional and Sustained Response’ in Mesothelioma Patient
There may be a new treatment option on the horizon for mesothelioma patients whose cancer has come back again after treatment. Researchers in the UK are even predicting that this drug could become the new standard of care for relapsed malignant mesothelioma. The drug is nivolumab, a PD-1 inhibitor sold under the brand name Opdivo. Already approved for the treatment of recurrent non-small cell lung cancer, nivolumab has been shown in recent clinical trials to reduce the size of mesothelioma tumors and may even extend mesothelioma survival. Opdivo in the News If you think you have been hearing more about nivolumab in the news lately, you are right. Laboratory results have suggested that this immunotherapy drug could be one of … Continue reading Nivolumab a ‘Rising Star’ for Malignant Mesothelioma Treatment?
AstraZeneca’s immunotherapy drug tremelimumab may still have a chance as a novel mesothelioma treatment, even though an international clinical trial completed last year found that it did not extend mesothelioma survival. In a new study published in The Lancet Respiratory Medicine, Italian researchers report that combining the monoclonal antibody with another drug called durvalumab “appeared active” as a second-line mesothelioma treatment with “a good safety profile”. Tremelimumab’s Rocky Start as a Mesothelioma Treatment Hopes were initially high for tremelimumab, a monoclonal antibody that works by binding to the protein CTLA-4 on the surface of white blood cells and preventing it from inhibiting the cells’ cancer-fighting power. The US even granted tremelimumab “orphan drug” status in 2015, a designation designed to … Continue reading Immunotherapy Combo Shows Early Efficacy for Malignant Mesothelioma
The results are in on the Phase I/II trial of the mesothelioma drug ONCOS-102 and researchers say there is reason to be excited. As Surviving Mesothelioma first reported in the fall of 2016, ONCOS-102 and standard chemotherapy significantly slowed the growth of malignant mesothelioma tumors in preclinical studies of infected mice. Now, the first human trial suggests that it can do the same thing in some human mesothelioma patients, boosting the effectiveness of standard chemotherapy and improving mesothelioma survival. Mesothelioma Study Results According to news released by Norway-based drug maker Targovax this week, three out of six patients with unresectable mesothelioma responded to a combination of ONCOS-102 and standard chemotherapy. In two patients, their mesothelioma tumors stopped growing and in … Continue reading New Immunotherapy Drug Stops Mesothelioma in Half of Patients Tested
Patients with malignant mesothelioma who have not gotten better after chemotherapy are being invited to enroll in a clinical trial of a combination drug that could be the future of mesothelioma treatment. The drug is called SEL-403. Developed by Selecta Biosciences, the drug seeks to get around the problem of the body producing antibodies that decrease the effectiveness of certain mesothelioma drugs. What is SLE-403 and How Could it Improve Mesothelioma Treatment? SEL-403 is a combination of two agents, The first is LMB-100, an immunotoxin that targets the protein mesothelin, which is overproduced by most mesothelioma tumors as well as by several other types of cancer cells. Since LMB-100 targets this particular protein, it is less likely to attack healthy … Continue reading Mesothelioma Patients Recruited to Test Promising New Combo Drug
Researchers at Stanford University are about to move into human trials of what some believe may be the most promising treatment yet for malignant mesothelioma and other types of solid tumors. The new treatment is an immunotherapy vaccine that combines two separate agents, both of which are already being tested independently. Unlike some other types of immunotherapy – including drugs like Keytruda and Opdivo that have been tested for mesothelioma treatment – the new treatment is not customized to attack a specific type of cancer cell. Instead, it relies on a two-part system that “teaches” immune system T-cells what kind of cells to attack by injecting the vaccine directly into a tumor. This is known as “in situ” … Continue reading A Cure for Mesothelioma? Hopes High for New Cancer Vaccine
Researchers at one of the nation’s top cancer institutes are betting on a combination of radiation and immunotherapy in the continued pursuit of better treatments for malignant mesothelioma. Memorial Sloan Kettering in New York is now recruiting relapsed mesothelioma patients into a safety and efficacy study of stereotactic body radiation therapy (SBRT) and the immunotherapy drug avelumab. The new trial is based on the idea that radiation may boost the immune system’s anti-mesothelioma response and that avelumab may enhance the effect. “The combination of radiation therapy and immunotherapy may be more effective against mesothelioma than either treatment alone,” writes lead researcher and radiation oncologist Andreas Rimner, MD, in a summary of the new study. SBRT in Mesothelioma Treatment The first … Continue reading New Mesothelioma Treatment Combines Immunotherapy and Targeted Radiation
Doctors at Wake Forest University are using miniature lab-grown three dimensional tumors to test personalized mesothelioma treatments. The mini-tumors are known as organoids and are grown from biopsy tissue taken from patients diagnosed with mesothelioma. Researchers say they can serve as models to try out new mesothelioma therapies before using them on patients. “There is a need for model systems to help predict personalized responses to chemotherapeutics,” writes lead investigator Andrea R. Massocchi with the Wake Forest Institute for Regenerative Medicine. “We have microengineered 3D tumor organoids directly from fresh tumor biopsies to provide patient-specific models with which treatment optimization can be performed before initiation of therapy.” Personalized Medicine and Malignant Mesothelioma Precision medicine in an up-and-coming area of medicine … Continue reading Mini-Tumors May Help Doctors Develop Personalized Mesothelioma Treatments